Monday, September 07, 2020 12:41:36 PM
REGARDS FDA:
I have no illusion about the effect corruption is going to have on our chances of an approval for ANYTHING in the US. Maybe a slim chance for HIV, but the chances of COVID are nil here due to FDA slow roll tactics. If you believe Fauci and the Administration, a vaccine is imminent before the election. They could care less if it works - they just need some data saying it is safe. That will occur before we get a S/C interim answers from the DSMC. Translation, no need for a therapeutic approval, imo.
THE ONLY WAY we get COVID approval is overseas, and I have no illusion that WS and BP have very long reaches to block us in all but the smallest countries or those with dictators who can unilaterally approve Leronlimab. Therefore it is imperative we have operating capital to survive the long run.
Leron is an absolute winner and will have myriad applications as well as a likely application in concert with many other drug treatments. As a large shareholder, I have put my money where my mouth is. But many on this forum seem to discount the long term likelihood of a payout on our investment. This will cause them to lose faith when euphoric prognostications of imminent approvals don’t pan out.
Until I see otherwise from revenue producing news, I will remain skeptical. The forces allied against us are evil to the point of letting people and economies die needlessly to protectt their turf and profits. They are a measure of the corruption manifest throughout US institutions today, and so far, no one seems to be able to stop them. Expect more promises of future meetings, data reviews, trial approvals, etc. They won’t ever say NO directly. They will simply try to string us along on waning hope while trying to bankrupt CytoDyn.
Our best hope is organic revolt by doctors, patients and investors to shine the light of justice on an utterly corrupt system holding us down. They are accomplices to murder at this point in my view.
STAY LONG, STAY STRONG!
I have no illusion about the effect corruption is going to have on our chances of an approval for ANYTHING in the US. Maybe a slim chance for HIV, but the chances of COVID are nil here due to FDA slow roll tactics. If you believe Fauci and the Administration, a vaccine is imminent before the election. They could care less if it works - they just need some data saying it is safe. That will occur before we get a S/C interim answers from the DSMC. Translation, no need for a therapeutic approval, imo.
THE ONLY WAY we get COVID approval is overseas, and I have no illusion that WS and BP have very long reaches to block us in all but the smallest countries or those with dictators who can unilaterally approve Leronlimab. Therefore it is imperative we have operating capital to survive the long run.
Leron is an absolute winner and will have myriad applications as well as a likely application in concert with many other drug treatments. As a large shareholder, I have put my money where my mouth is. But many on this forum seem to discount the long term likelihood of a payout on our investment. This will cause them to lose faith when euphoric prognostications of imminent approvals don’t pan out.
Until I see otherwise from revenue producing news, I will remain skeptical. The forces allied against us are evil to the point of letting people and economies die needlessly to protectt their turf and profits. They are a measure of the corruption manifest throughout US institutions today, and so far, no one seems to be able to stop them. Expect more promises of future meetings, data reviews, trial approvals, etc. They won’t ever say NO directly. They will simply try to string us along on waning hope while trying to bankrupt CytoDyn.
Our best hope is organic revolt by doctors, patients and investors to shine the light of justice on an utterly corrupt system holding us down. They are accomplices to murder at this point in my view.
STAY LONG, STAY STRONG!
Recent CYDY News
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
